The win is Abbott’s third in a row in federal court in Chicago where hundreds of cases over specialized formulas for preterm ...

Abbott Labs reported 6.9% sales growth in Q3 2025, led by medical devices and nutrition, while reaffirming full-year guidance ...

Medical devices continue to be a strong growth driver for Abbott, as the company battles its ongoing sales slump in ...

Abbott (NYSE: ABT) shares dipped before hours today on third-quarter results that fell short of the consensus Wall Street ...

Abbott reported higher quarterly revenue on Wednesday, driven by strong demand for its medical devices including continuous ...

Abbott’s strong Q3, global diversification, and resilient portfolio support long-term growth despite diagnostics softness and ...

Benchmark anticipates that Abbott’s Diagnostics business will pick up speed again in 2026 with the introduction of a new ...

Abbott missed analysts' third-quarter revenue estimates on Wednesday, as weakness in its diagnostics and nutrition businesses outweighed robust demand for its medical devices.

Abbott trimmed its earnings forecast as the Trump administration launched an investigation into medical device imports that ...

According to a filing with the Securities and Exchange Commission dated October 14, 2025, CCLA Investment Management ...

There are significant advantages to holding shares of companies for a long time as opposed to, say, day trading. The ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.